XBiotech (NASDAQ:XBIT) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of XBiotech (NASDAQ:XBIT) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

XBiotech Stock Up 2.8 %

NASDAQ XBIT opened at $3.81 on Friday. The company has a 50-day simple moving average of $4.10 and a two-hundred day simple moving average of $4.76. The firm has a market cap of $115.82 million, a price-to-earnings ratio of -3.20 and a beta of 1.41. XBiotech has a 12-month low of $3.00 and a 12-month high of $6.69.

Hedge Funds Weigh In On XBiotech

A number of institutional investors have recently bought and sold shares of XBIT. Millennium Management LLC increased its stake in shares of XBiotech by 1,602.0% during the second quarter. Millennium Management LLC now owns 284,679 shares of the biopharmaceutical company’s stock valued at $1,603,000 after purchasing an additional 267,953 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of XBiotech during the second quarter valued at approximately $443,000. Credit Suisse AG increased its position in shares of XBiotech by 45.1% during the second quarter. Credit Suisse AG now owns 226,147 shares of the biopharmaceutical company’s stock valued at $1,273,000 after acquiring an additional 70,294 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of XBiotech by 50.8% during the first quarter. Dimensional Fund Advisors LP now owns 153,918 shares of the biopharmaceutical company’s stock valued at $1,330,000 after acquiring an additional 51,872 shares in the last quarter. Finally, EA Series Trust bought a new stake in shares of XBiotech during the second quarter valued at approximately $296,000. 11.45% of the stock is owned by institutional investors.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.